Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
FUJIFILM Cellular Dynamics Introduces Human iPSC-derived Sensory Neurons to Advance Pain Research
MADISON, Wis., September 10, 2024 – FUJIFILM Cellular Dynamics, a leading global developer and manufacturer of human induced pluripotent stem cells (iPSCs) today announces the global commercial launch of its human iPSC-derived iCell® Sensory Neurons for scientists engaged in neuroscience research, drug discovery of novel pain medications, and analysis of neurotoxicity side effects. FUJIFILM Cellular Dynamics will present iCell Sensory Neurons and other key products in its market-leading neuroscience portfolio at the Society for Neuroscience annual conference in Chicago from October 5-9, 2024 and the Annual Pain Therapeutics Summit in Boston from October 28-29, 2024. [Read more…]
Ncardia Launches Panel of Ready-to-Use Assays to Streamline Screening and Selection of New Therapeutic Candidates
New assays based on iPSC help accelerate drug discovery by giving drug innovators in neurodegenerative diseases high quality data on a broad range of disease-relevant read-outs.
September 10, 2024, LEIDEN, Netherlands — Ncardia, a leading human iPSC company, announced today the launch of a new panel of ready-to-use assays designed to streamline the screening and selection of new therapeutic candidates, with a specific focus on neurodegenerative diseases. [Read more…]
BlueRock Receive FDA clearance of IND for Investigational iPSC-derived Cell Therapy OpCT-001
BlueRock Therapeutics announces FDA clearance of IND application for investigational iPSC-derived cell therapy OpCT-001 for the treatment of primary photoreceptor diseases
Cambridge, MA USA, Sept. 03, 2024 — BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for OpCT-001, an investigational induced pluripotent stem cell (iPSC)-derived cell therapy for the treatment of primary photoreceptor diseases. [Read more…]
SCG Cell Therapy And A*Star Launch Joint Labs With S$30M To Advance iPSC Technology for Scalable GMP Manufacturing Of Cellular Immunotherapies
-
Collaboration aims to develop scalable GMP-grade iPSC manufacturing processes and therapeutic candidates to facilitate research leading to translation of novel cellular immunotherapies.
-
Launch of the joint labs builds on existing license, research collaboration and Memorandum of Understanding between SCG Cell Therapy and A*STAR.
August 16, 2024, Singapore – SCG Cell Therapy (SCG) and the Agency for Science, Technology and Research (A*STAR) announced the launch joint laboratories for cellular immunotherapies. This collaboration, at a combined funding of close to S$30 million supported under Singapore’s Research, Innovation and Enterprise 2025 Plan (RIE2025), aims to advance the development of induced pluripotent stem cell (iPSC) technology to produce novel cell therapies that meet Good Manufacturing Practice (GMP) standards. The collaboration will also establish a talent development programme to train the next generation of experts in this field, in accordance with current GMP and regulatory requirements. [Read more…]
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 144
- Next Page »